Literature DB >> 6213200

Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates.

M Y Khan, R P Gruninger, S M Nelson, R E Klicker.   

Abstract

The in vitro activity of a new oral antimicrobial agent, norfloxacin (MK-0366), was compared with those of nalidixic acid, nitrofurantoin, co-trimoxazole, trimethoprim, sulfamethoxazole, cinoxacin, tetracycline, ampicillin, carbenicillin, and cephalexin against 628 urinary bacterial isolates. Norfloxacin was the most active antimicrobial agent tested against the gram-negative bacilli. It was less active than a few of the other antimicrobial agents against enterococci and Staphylococcus aureus.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6213200      PMCID: PMC182027          DOI: 10.1128/AAC.21.5.848

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  2 in total

1.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

2.  Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections.

Authors:  K Hirai; A Ito; Y Abe; S Suzue; T Irikura; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

  2 in total
  23 in total

1.  Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis.

Authors:  T Sandberg; G Englund; K Lincoln; L G Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-05       Impact factor: 3.267

2.  Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers.

Authors:  R D Cofsky; L duBouchet; S H Landesman
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

3.  Multicenter evaluation of the proposed quality control limits and interpretive zone standards for in vitro susceptibility testing with norfloxacin.

Authors:  D L Shungu; V Tutlane; H H Gadebusch
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

4.  In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patients.

Authors:  I Garcia; G P Bodey; V Fainstein; D H Ho; B LeBlanc
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

5.  Antibacterial activity of norfloxacin against bacterial isolates from the urinary tract.

Authors:  S M Qadri; S Johnson
Journal:  J Natl Med Assoc       Date:  1989-04       Impact factor: 1.798

6.  Inappropriate breast secretions of possible bacterial etiology in the parous nonpuerperal female.

Authors:  J J Freeman; R H Altieri; A H Freeman; T Kuo; F Sardinha; C C Buckingham; J J Sklar; K Dyroff; A Floyd
Journal:  J Natl Med Assoc       Date:  1994-03       Impact factor: 1.798

7.  In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.

Authors:  S Nakamura; A Minami; H Katae; S Inoue; J Yamagishi; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

8.  In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.

Authors:  J D Gay; D R DeYoung; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

9.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

Review 10.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; D M Richards
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.